Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Myriad. Show all posts
Showing posts with label Myriad. Show all posts
Wednesday, May 09, 2012

Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

›
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0 Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned sub...
Saturday, May 05, 2012

paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)

›
US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology US firm corners exclusive license for RAD51C cancer ge...
Tuesday, March 27, 2012

media: AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes (BRCA/ovarian....)

›
Blogger's Note: typical reminder that the Myriad 'breast cancer' genetic testing is not only for breast cancer AMP Optimist...
Monday, March 26, 2012

Reuters: Myriad gene patent ruling sent back to lower court

›
  Reuters: Myriad gene patent ruling sent back to lower court "The move is expected to delay a verdict in the Myriad case by as much ...
Friday, March 23, 2012

Myriad Genetics slips on patent concerns - BusinessWeek

›
Myriad Genetics slips on patent concerns - BusinessWeek

Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release)

›
Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release) : Myriad Genetics Announces the Release o...
Monday, March 19, 2012

Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing (BRCA patients)

›
1 comment:
Friday, March 02, 2012

[Lancet Oncology News] US firm corners exclusive license for RAD51C cancer gene

›
[News] US firm corners exclusive license for RAD51C cancer gene : "Already facing a legal challenge to its BRCA1 and BRCA2 patents...
Sunday, February 19, 2012

Myriad Genetics’ Australian Cancer Gene Patents Go on Trial in Sydney, Australia - Bloomberg

›
Friday, February 17, 2012

Patents on Genetic Data Raise Legal Questions on Rights to DNA - Bloomberg

›
Thursday, February 16, 2012

US firm (Myriad) corners exclusive license for RAD51C (breast/ovarian)cancer gene : The Lancet Oncology

›
 abstract Bryant Furlow "Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT,...
Thursday, February 09, 2012

open access: BMC Cancer - Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries (Lynch Syndrome)

›
 Background Lynch syndrome (LS) is the most common form of inherited predisposition to colorectal cancer (CRC), accounting for 2–5% of...
Thursday, February 02, 2012

Myriad Cert Petition Now Fully Briefed; Supreme Court May Decide by Feb. 20 | Bloomberg BNA

›
Thursday, January 26, 2012

Jan 2012 BRCA patent dispute may head to US Supreme Court : The Lancet

›
"The long-running dispute over patents for the BRCA1 and BRCA2 genes granted to Myriad Genetics may finally be laid to rest by the US...
Thursday, January 19, 2012

Myriad Genetics Gets (Worldwide) Rights To RAD51C Gene

›
"...Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial...
Friday, July 29, 2011

Gene Patent (Myriad) in Cancer Test Upheld by Appeals Panel - NYTimes.com (BRCA 1/2)

›
Monday, March 07, 2011

Editorial - Human gene patents limit access to care :: March 7, 2011 ... American Medical News

›
Friday, March 04, 2011

Genetics Company Myriad May Shift From Patents To Proprietary Data | Intellectual Property Watch

›
Wednesday, March 02, 2011

How Will Myriad Respond to the Next Generation of BRCA Testing? GenOmics

›
Monday, October 11, 2010

A Do-It-Yourself Genomic Challenge to Myriad, the FDA and the Future of Genetic Tests (long)

›